Bowel cancer screening set to save thousands of lives

Reata Pharmaceuticals, Inc. has announced that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.

Full Post: FDA grants orphan drug status to Reata’s pancreatic cancer drug

Bowel cancer screening is predicted to save over two and a half thousand lives every year in the UK by 2025, according to new research published in the Journal of Medical Screening*.

The Cancer Research UK funded study, which looked at the impact home testing kits could have on mortality rates, showed that deaths from bowel cancer are set to drop by around 16 per cent.

By 2025, the numbers of lives that are expected to be saved in the UK each year is between 2200 and 2700.

The faecal occult blood testing kit tests for traces of blood in peoples’ stools, which can be an early sign of bowel cancer. Detecting the early signs of the disease significantly increases the chance of survival - four out of five people diagnosed at an early stage recover.

The researchers used a computer simulation model - based on mortality and incidence rates between 1975 and 2004 and the number of people that attended screening in early trials - to see the impact that the screening programme would have over the next 20 years.

Study author Dr Max Parkin, Cancer Research UK epidemiologist at Queen Mary University of London, said: “The results of our study show the large number of lives that could be saved by the national bowel cancer screening programme in the next 20 years. Cancer of the bowel is a major problem in the UK for both men and women - it is the second most common cause of cancer death. Screening every two years for people aged between 60 and 74 years old is absolutely crucial in order to reduce the number of people dying from bowel cancer.

“In this study we’re assuming that between 60 and 80 per cent of people will take up the opportunity to be screened. But, if we can encourage more people to take part then we would hope to save even more lives.”

Sara Hiom, director of health information at Cancer Research UK, said: “The screening programme, which started in 2007, aims to detect bowel cancer at an early stage. If it is caught early then treatment is likely to be simpler and much more effective.

“This report highlights how successful screening could be but, worryingly, there are still a large number of people not using the testing kits. This type of screening is non-invasive and anonymous - it’s just a case of doing the test at home and sending a sample off for analysis. It’s so simple yet could save your life. Forgetting to do it or feeling too embarrassed could have serious consequences. We urge everyone who is sent the kit in the post to take part so that more lives can be saved.”

To listen to Dr Parkin talking about his research to Laura Dibb, Cancer Research UK press officer click here

* Predicting the Impact of the Screening Programme for Colorectal Cancer in the UK D.M.Parkin et al online publication 23 December 2008 Journal of Medical Screening. The Journal of Medical Screening is published by RSM Press, the publishing wing of the Royal Society of Medicine. The Journal is concerned with all aspects of medical screening, particularly the publication of research that advances screening theory and practice. It aims to increase awareness of the principles of screening (quantitative and statistical aspects), screening techniques and procedures and methodologies from all specialties.


According to the latest information cancer is on the increase in Australia. In a report by the Australian Institute of Health and Welfare on cancer statistics for 2008 new cancer cases are expected to increase by over 3,000 cases per year. The report shows that the number of new cancer cases diagnosed in Australia each

Full Post: Cancer is on the increase in Australia

A study to assess the feasibility of undertaking a UK-based screening trial for lung cancer has been commissioned by the National institute for Health Research Health Technology Assessment (NIHR HTA) programme. Lung cancer kills more people worldwide than any other malignancy accounting for around 1.4 million deaths each year, and around 38,000 individuals are diagnosed

Full Post: Lung cancer screening feasibility study funded

A new study by Narendra et al. suggests that Parkin, the product of the Parkinson’s disease-related gene Park2, prompts neuronal survival by clearing the cell of its damaged mitochondria. “[This is] an exciting new discovery that links the fields of mitochondrial quality control and the genetics of Parkinson’s disease (PD),” writes Heidi McBride of the

Full Post: Researchers shed new light on genetics of Parkinson’s

Just under five per cent of the men who took part in the prostate cancer element of the USA’s largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the UK-based urology journal BJU International.

Full Post: Prostate cancer screening programme shows high compliance and consistent results in more than 38,000 men

The use of human papillomavirus (HPV) DNA testing as an initial screening step followed by triage with a standard Pap test (cytology) and repeat HPV DNA testing may increase the accuracy of cervical cancer screening, according to a study in the Jan. 13 online issue of the Journal of the National Cancer Institute. Compared to

Full Post: HPV testing followed by cytology and repeat HPV testing may improve cervical cancer screening